Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis

Needs Statement

This CME activity is designed to meet the educational needs of primary care physicians, specialists in internal medicine and oncology, physician assistants, nurse practitioners, fellows, residents, and other healthcare professionals.

Educational Objectives

At the conclusion of this activity, the participant should be able to:

• Apply current United States Preventive Services Task Force (USPSTF) guidelines to screening for viral hepatitis
• Identify which laboratory tests are most appropriate for diagnosis
• Assess whether or not a patient requires vaccination for hepatitis B
• Distinguish which patients require referral to specialty care

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Director

Maya Balakrishnan, M.D., M.P.H.
Assistant Professor of Medicine
Department of Gastroenterology
Baylor College of Medicine
Houston, Texas
Disclosure: Research Support: Intercept, Gilead

Term of Approval

February 1, 2018 through February 29, 2020. Original release date: February 1, 2018

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.